Atamyo Therapeutics, a biotechnology company specializing in the development of next-generation gene therapies for limb-girdle muscular dystrophy (LGMD),...
As artificial intelligence becomes increasingly embedded in formulation science and early clinical planning, the industry faces a dual challenge: accelerat...
As life sciences companies scale biologics, advanced therapies, and personalized medicines, sustainability has moved from aspiration to operational imperat...
As biologic modalities grow more complex and timelines compress, the operational relationship between contract development and manufacturing organizations ...
First Investigational Gene Therapy for Pitt Hopkins Syndrome Intended to Address Underlying Disease Biology -- Mahzi Therapeutics Inc., a clinical...
Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA), see...
Under the leadership of Joel Latham, Incannex Healthcare is advancing a differentiated pipeline of cannabinoid- and psychedelic-based thera...
Endoplasmic reticulum (ER) stress and the unfolded protein response are often implicated in the progression of metabolic dysfunction-associated stea...
A new survey-based Genomics Tracker focused on the EU-5 (France, Germany, Italy, Spain, and the United Kingdom) by DeciBio Consulting LLC provides update...
Celltrion, Inc. announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) in...
Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Pre...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announced financial results for the fourth quarte...
Belén Garijo to become Chief Executive Officer of Sanofi Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Direc...
Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over-Year to $1...
© 2026 Biopharma Boardroom. All Rights Reserved.
